Japan’s Shimadzu Corporation announced this month that its US subsidiary, Shimadzu Scientific Instruments (SSI), has established a new R&D center in the US, and is planning to strengthen its product development capabilities and technology for its work with pharmaceutical companies.
The R&D center consists of the Maryland headquarters attached to the SSI headquarters, and new locations near Boston and San Francisco that will work on prototypes developed with the company’s customers. The company’s Maryland headquarters will include a collaboration lab to conduct joint research with customers.
Shimadzu Corporation says it plans to increase parent company Shimadzu Group’s sales in North America from 51 billion yen ($330 million) in 2022 to over 70 billion yen ($452 million) in 2025 by leveraging SSI’s bases to expand its business to pharmaceutical companies.
“We will work closely with pharmaceutical companies to assess their needs and proceed with the development of products (such as analytical and measuring instruments). In addition to the small molecule drugs that SSI has previously collaborated with pharmaceutical companies on, we will also contribute to the development of biopharmaceuticals,” said a Shimadzu spokesperson.
This article was written by Norika Yamaji.